Adherence to guidelines in the use of biological agents to treat psoriasis in Brazil

Author(s)

do Nascimento Silveira, Miriam Sanches ^[1] ; de Camargo, Iara Alves ^[1] ; Serpa Osorio-de-Castro, Claudia Garcia ^[2] ; Barberato-Filho, Silvio ^[1] ; Del Fiol, Fernando de Sa ^[1] ; Guyatt, Gordon ^[3] ; de Camargo, Mayara Costa ^[1] ; Lopes, Luciane Cruz ^[1]

Affiliation

^[1] Univ Sorocaba, Programa Posgrad Ciencias Farmaceut, Sao Paulo - Brazil

^[2] Fundacao Oswaldo Cruz Fiocruz, Escola Nacl Saude Publ Sergio Arouca, Nucelo Assistencia Farmaceut, Rio De Janeiro - Brazil

^[3] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON - Canada

• Document type: Journal article
• Source: BMJ OPEN; v. 4, n. 3 2014.
• Web of Science Citations: 4

Abstract

Objective In Sao Paolo, Brazil, patients can appeal to the courts, registering law suits against the government claiming the need for biological agents for treatment of psoriasis. If the lawsuits are successful, which is usually the case, the government then pays for the biologic agent. The extent to which the management of such patients, after gaining access to government payment for their biologic agents, adheres to authoritative guidelines, is uncertain. Methods We identified patients through records of the State Health Secretariat of Sao Paulo from 2004 to 2011. We consulted guidelines from five countries and chose as standards only those recommendations that the guidelines uniformly endorsed. Pharmacy records provided data regarding biological use. Guidelines not only recommended biological agents only in patients with severe psoriasis who had failed to respond to topical and systemic therapies (eg, ciclosporin and methotrexate) but also yearly monitoring of blood counts and liver function. Results Of 218 patients identified in the database, 3 did not meet eligibility criteria and 12 declined participation. Of the 203 patients interviewed, 91 were still using biological medicine; we established adherence to laboratory monitoring in these patients. In the total sample, management failed to meet standards of prior use of topical and systemic medication in 169 (83.2%) patients. Of the 91 patients using biological medicine at the time of the survey, 23 (25.2%) did not undergo appropriate laboratory tests. Conclusions Important discrepancies exist between clinical practice and the recommendations of guidelines in the management of plaintiffs using biological drugs to treat psoriasis. (AU)

• FAPESP's process: 09/53084-1 - Analysis of lawsuits for access to treatment of rheumatoid arthritis and psoriasis in the State of São Paulo, Brazil - PSAR
• Grantee: Luciane Cruz Lopes
• Support Opportunities: Research Grants - Research in Public Policies for the National Health Care System (PP-SUS)